Julian Harrison
Stock Analyst at BTIG
(1.20)
# 3,333
Out of 4,818 analysts
41
Total ratings
33.33%
Success rate
-11.68%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $4.95 | +708.08% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $11.64 | +260.82% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.30 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $20.42 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.55 | +480.65% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.20 | +569.46% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $1.85 | +332.43% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $13.55 | +350.35% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $3.97 | +277.83% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $13.58 | +84.09% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $46.20 | +10.39% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.74 | - | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $6.84 | +528.65% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $14.29 | +179.92% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.44 | +122.46% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $36.59 | +17.52% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $2.16 | +85.19% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.57 | +26,005.12% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $39.58 | -9.04% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $293.46 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $4.95
Upside: +708.08%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $11.64
Upside: +260.82%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.30
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $20.42
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.55
Upside: +480.65%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.20
Upside: +569.46%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $1.85
Upside: +332.43%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $13.55
Upside: +350.35%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $3.97
Upside: +277.83%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $13.58
Upside: +84.09%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $46.20
Upside: +10.39%
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.74
Upside: -
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $6.84
Upside: +528.65%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $14.29
Upside: +179.92%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $9.44
Upside: +122.46%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $36.59
Upside: +17.52%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $2.16
Upside: +85.19%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.57
Upside: +26,005.12%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $39.58
Upside: -9.04%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $293.46
Upside: -